GlassScriptPhysician profile
Anna M Little
NPI 1982801742
$1,810.70
in general payments reported to CMS, 2019-2025
25 companies · $818 in 2025
The $818 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.30 · 2021: $137 · 2022: $235 · 2023: $338 · 2024: $264 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,419.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $395.44 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $195.76 | 2021-2025 | Breztri, Farxiga |
| Braeburn INC. | $171.12 | 2024-2025 | Brixadi |
| Exact Sciences Corporation | $163.67 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Indivior INC. | $130.29 | 2025 | Sublocade |
| Abbvie INC. | $127.77 | 2021-2023 | |
| Glaxosmithkline, LLC. | $110.04 | 2022-2025 | Bexsero, Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $98.40 | 2022 | |
| Sanofi Pasteur INC. | $82.13 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $43.98 | 2025 | Daybue |
| Xeris Pharmaceuticals, INC. | $38.14 | 2022-2024 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $27.24 | 2025 | Rexulti |
| Viiv Healthcare Company | $26.66 | 2025 | Apretude |
| Merck Sharp & Dohme LLC | $22.89 | 2024 | Capvaxive, Vaxneuvance |
| Insulet Corporation | $19.94 | 2025 | Omnipod |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $19.30 | 2019 | |
| Amgen INC. | $18.33 | 2024 | Repatha, Otezla |
| Lilly USA, LLC | $17.91 | 2023 | Mounjaro, Jardiance |
| Dexcom, INC. | $16.98 | 2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $16.81 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.19 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.67 | 2024 | Synjardy, Jardiance |
| Pfizer INC. | $13.81 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.28 | 2022 | |
| Axsome Therapeutics, INC. | $10.95 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Little listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.